Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach

Han Pil Lee¹, Jae Kwang Yun², Hee Suk Jung³, Duk Hwan Moon⁴, Geun Dong Lee², Sehoon Choi², Yong-Hee Kim², Dong Kwan Kim², Seung Il Park² and Hyeong Ryul Kim²*

Abstract

Background: The role of surgical intervention as a treatment for pulmonary metastasis (PM) from hepatocellular carcinoma (HCC) has not been established. In this study, we investigated the clinical outcomes of pulmonary metastasectomy. Using propensity score matching (PSM) analysis, we compared the results according to the surgical approach: video-assisted thoracic surgery (VATS) versus the open method.

Methods: A total of 134 patients (115 men) underwent pulmonary metastasectomy for isolated PM of HCC between January 1998 and December 2010 at Seoul Asan Medical Center. Of these, 84 underwent VATS (VATS group) and 50 underwent thoracotomy or sternotomy (open group). PSM analysis between the groups was used to match them based on the baseline characteristics of the patients.

Results: During the median follow-up period of 33.4 months (range, 1.8–112.0), 113 patients (84.3%) experienced recurrence, and 100 patients (74.6%) died of disease progression. There were no overall survival rate, disease-free survival rate, and pulmonary-specific disease-free survival rate differences between the VATS and the open groups (p = 0.521, 0.702, and 0.668, respectively). Multivariate analysis revealed local recurrence of HCC, history of liver cirrhosis, and preoperative alpha-fetoprotein level as independent prognostic factors for overall survival (hazard ratio, 1.729/2.495/2.632, 95% confidence interval 1.142–2.619/1.571–3.963/1.554–4.456; p = 0.010/< 0.001/< 0.001, respectively).

Conclusions: Metastasectomy can be considered a potential alternative for selected patients. VATS metastasectomy had outcomes comparable to those of open metastasectomy.

Keywords: Hepatocellular carcinoma, PM, Metastasectomy, Video-assisted thoracoscopic surgery (VATS)
**Introduction**

Hepatocellular carcinoma (HCC) is one of the most frequent malignancies in Asia, including Korea [1], and ranks third in cancer deaths worldwide [2]. In the recent years, the postoperative morbidity and mortality rates from HCC have improved; however, long-term outcomes remain poor due to extrahepatic metastasis and intrahepatic recurrence after surgical management. The most frequent site of metastasis and of the first detectable metastasis was reported to be the lungs [3, 4]. However, appropriate management for pulmonary metastasis (PM) has not been established, and systemic chemotherapy has been reported to be largely ineffective [5]. The results of the multi-national, randomized, placebo-controlled, phase III sorafenib HCC Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib significantly improved the overall survival in patients with advanced HCC and well-preserved liver function, and that drug-related adverse events were manageable [6]. However, according to the subanalysis of phase II sorafenib Asia-Pacific trial, the effectiveness of sorafenib in advanced HCC patients remains unclear as the survival gain in patients with PM was only 1.4 months (hazard ratio [HR] 0.87) [7]. Although sorafenib has been a standard regimen for advanced HCC, its effectiveness is marginal in the presence of PM. In most cases, the lesions of extrahepatic metastasis from HCC are not resectable. Therefore, surgical treatment of PM has not been applied as a standard therapy in PM from HCC.

In some reports, pulmonary resection for PM from HCC resulted in long-term survival in highly selected patients [8-10]. Usually, wedge resection through open thoracotomy has been performed for superficial lesions, and segmentectomy or lobectomy is needed for deeper lesions. With recent advances in VATS and diagnostic modalities, such as multi-detector row computed tomography (CT), minimally invasive and complete metastasectomy can be provided to chronically ill patients with HCC and PM [1-14]. However, the use of surgical resection and VATS for PM of HCC remains controversial. We believe that an appropriate surgical role is needed for the treatment of patients with advanced HCC. In this study, we investigated the clinical outcomes of pulmonary metastasectomy and the risk factors for survival rate and disease-free survival rate in patients of HCC with PM. Using propensity score matching (PSM) analysis, we compared the results according to surgical approach: VATS versus open thoracotomy or sternotomy methods.

**Methods**

**Patients**

In this study, we retrospectively reviewed a total of 1085 patients who had undergone metastasectomy due to thoracic metastasis from HCC between January 1998 and December 2010. Of these, 852 cases with different histology and 18 cases with metastatic lesions in the thorax other than the lung were excluded. Sixty-one cases were further excluded due to duplicated patients. Ten patients had concurrent malignancies, and 3 cases were diagnosed with a different histology from HCC. After excluding 7 cases with incomplete medical records, we retrospectively 134 patients (115 men) who had undergone pulmonary metastasectomy for isolated PM of HCC. The enrollment of patients is shown in Fig. 1. The inclusion criteria of our study were as follows: (1) controlled state of primary HCC, (2) no other distant metastasis, and (3) appropriate pulmonary function test for major lung resection. All patients had available follow-up till December 2015.

**Methodology**

Eighty-four patients underwent VATS (VATS group), and 50 underwent thoracotomy or sternotomy (open group). Under general anesthesia and double-lumen endotracheal tube insertion for single-lung ventilation, the patients’ chest that is where the lesion is located was up on the degree of 90°. Three or four surgical ports were created for VATS, and posterolateral thoracotomy or median sternotomy was performed for open surgery. Surgical approaches such as thoracotomy, sternotomy, and VATS were determined depending on the size, number, location, and laterality of the metastatic nodules. VATS can be applied for lesions of sizes below 3 cm, located in the outer one-third of the lung, having no endobronchial extension. The metastatic lesion located in the periphery of the lung was non-problematically resected by wedge resection. Segmentectomy or lobectomy was needed for deeply located lesions. Mediastinal lymph node dissections were performed only if enlarged lymph nodes were revealed on chest CT. This study was approved by the Asan Medical Center Ethics Committee/Review Board (2019-1166).

**Statistical analysis**

Time-to-pulmonary recurrence after the initial treatment (TPR) was defined as the interval between control of HCC and the diagnosis of PM. Disease-free survival (DFS) after the first pulmonary metastasectomy was defined as the interval between the first pulmonary metastasectomy and diagnosis of a lesion related to HCC after the first pulmonary metastasectomy. Pulmonary DFS after metastasectomy (PDFS) was defined as the interval between the first pulmonary metastasectomy and the diagnosis of the second PM. Overall survival time was measured by comparing the date of the first pulmonary metastasectomy to the date of death or the last follow-up. Preoperative alpha-fetoprotein (AFP) was defined as the value of the latest serum AFP level measured before the first metastasectomy. Postoperative AFP was defined...
as the value of the earliest measured serum AFP level after the first metastasectomy, within 2 months. The calculation of the BCLC stage was based on before lung metastasis was detected. This is because, based on the time after lung metastasis is found, all patients are at BCLC stage c or higher, and other variables of the patient before surgery may not be considered. Categorical variables were expressed as frequencies and percentages and were compared between the two approaches using the chi-square test or Fisher’s exact test. Continuous variables were shown as means with standard deviations or median values with range and were compared using a Student’s t test. Univariate and multivariate analyses for prognostic factors were performed using Cox’s proportional hazard model. Survival rates were estimated using the Kaplan-Meier method, and survival according to the prognostic factors was compared using a log-rank test. Cox proportional hazard models were used to identify the predictors of mortality and recurrence. After excluding the correlated variables, independent variables with \( p \) values ≤ 0.05 from the univariate analysis were used for the initial multivariate Cox. The final multivariable model was selected using forward stepwise selection (\( p \) value ≤ 0.10 for entering the model and \( p \leq 0.05 \) for staying in the model).

There were several considerations (baseline characteristics, HCC factors, surgical factors) for PSM; 13 variables (age, sex, history of liver cirrhosis, level of initial AFP, etiology of HCC, BCLC stage of HCC, Child-Pugh score, Eastern Cooperative Oncology Group (ECOG) scale of performance status, treatment method for primary HCC, local recurrence or progression of HCC, number of PM, maximum diameter of PM, TPR) were used for PSM. For PSM, observation pairs with equivalent propensity scores were selected with nearest-neighbor matching and a caliper width of 0.2 standard deviation. Patients in the VATS group were randomly matched to patients in the open group at a ratio of 1:1. The final sample consisted of 32 matched patients in each group.

Statistical analyses were performed using SPSS version 21.0 (SPSS Inc. Armonk, NY, USA) and R version 3.4.2 (R Project for Statistical Computing, Vienna, Austria). A value of \( p < 0.05 \) was considered statistically significant.

**Results**

The median age was 55.0 years (range, 24–76 years). Patient characteristics are summarized in Table 1.

Surgical treatment for primary HCC was performed in 107 patients (79.9%), liver cirrhosis was reported in 49
patients (36.6%), and local recurrence of HCC was found in 89 patients (66.4%). There were no significant differences in baseline and primary HCC characteristics between the VATS and open groups. Unilateral PM was found in 104 patients (77.6%), and the median number of PMs was 1.0 (range, 1–11). There was a significant difference in the size and number of metastatic nodules between the VATS and open groups (p = 0.039 and 0.009, respectively). Wedge resection was more frequently performed in the VATS group than in the open group. There was no operative mortality. The median overall survival time was 38.7 months (range, 4.4–172.3), and median TPR was 19.1 months (range, 5–95.9). Perioperative complications occurred in 6 (4.5%). Three patients had prolonged pleural effusion needing insertion of the chest tube, 2 patients had prolonged air leakage, and 1 patient had postoperative pneumonia. The median hospital days after metastasectomy was 5 days (range, 3–26), 4.0 days (range, 3–24) in the VATS group, and 7.0 days (range, 4–26) in the open group (p = 0.001) (Table 2).

For the median 33.4 months (range, 1.8–112.0) duration of the follow-up from first metastasectomy, 113 (84.3%) patients experienced recurrence: 63 (55.7%) in the lung, 26 (23.0%) in the liver, 13 (11.5%) in other single organs, and 9 (8.0%) in multiple organs. Pulmonary-specific recurrences were observed in 95 (70.9%) patients. Forty-three (45.3%) patients had ipsilateral pulmonary metastases. Forty-five (47.4%) patients underwent repeated metastasectomies, 27 (28.4%) patients received chemotherapy, 4 (4.2%) patients

| Table 1 Patients’ baseline and primary hepatocellular carcinoma characteristics |
|--------------------------------------------|-------------|-------------|-------------|
| Age (years) | Total (n = 134) | Open (n = 50) | VATS (n = 84) | p value |
|-------------|-----------------|--------------|--------------|---------|
| 54.4 ± 9.5 | 53.1 ± 9.2 | 55.1 ± 9.7 | 0.261 |
| Sex (male) | 115 (85.8%) | 45 (90.0%) | 70 (83.3%) | 0.285 |
| BCLC stage | | | | 0.206 |
| 0 | 4 (3.0%) | 0 | 4 (4.8%) |
| A | 34 (25.4%) | 15 (30.0%) | 19 (22.6%) |
| B | 49 (36.6%) | 18 (36.0%) | 31 (36.9%) |
| C | 43 (32.1%) | 14 (28.0%) | 29 (34.5%) |
| D | 4 (3.0%) | 3 (6.0%) | 1 (1.2%) |
| ECOG performance status | | | | 0.571 |
| 0 | 112 (83.6%) | 41 (82.0%) | 71 (84.5%) |
| 1 | 17 (12.7%) | 6 (12.0%) | 11 (13.1%) |
| 2 | 4 (3.0%) | 2 (4.0%) | 2 (2.4%) |
| 3 | 1 (0.7%) | 1 (2.0%) | 0 |
| 4 | 0 | 0 | 0 |
| Etiology | | | | 0.716 |
| HBV | 111 (82.8%) | 42 (84.0%) | 69 (82.1%) |
| HCV | 1 (0.7%) | 0 | 1 (1.2%) |
| Alcohol | 5 (3.7%) | 1 (2.0%) | 4 (4.8%) |
| Unknown | 17 (12.7%) | 7 (14.0%) | 10 (11.9%) |
| Child-Pugh classification | | | | 0.422 |
| A | 116 (86.6%) | 41 (82.0%) | 75 (89.3%) |
| B | 13 (9.7%) | 6 (12.0%) | 7 (8.3%) |
| C | 5 (3.7%) | 3 (6.0%) | 2 (2.4%) |
| Liver cirrhosis | 49 (36.6%) | 14 (28.0%) | 35 (41.7%) | 0.112 |
| Initial AFP (ng/ml) | 73.0 (1.0–585,000) | 60.7 (1.0–585,000) | 80.0 (1.0–485,000) | 0.601 |
| Treatment of HCC | | | | 0.171 |
| Surgery | 107 (79.9%) | 43 (86.0%) | 64 (76.2%) |
| TACE | 27 (20.1%) | 7 (14.0%) | 20 (23.8%) |
| RFA | 0 | 0 | 0 |

VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, PSM propensity score matching, ECOG Eastern Cooperative Oncology Group, TACE transarterial chemoembolization, RFA radiofrequency ablation
received radiation therapy, 2 (2.1%) patients received chemoradiation therapy, and in 17 (17.9%) patients, metastatic lesions remained for various reasons (Table 3). One hundred patients (74.6%) died of disease progression. The 1-, 3-, and 5-year overall survival rates after the first pulmonary metastasectomy were 85.8%, 53.7%, and 37.3%, respectively. Disease-free survival rates after the first pulmonary metastasectomy were 33.2% in 1 year, 23.7% in 3 years, and 20.4% in 5 years, respectively (Fig. 2).

Table 2 Characteristics of the first pulmonary metastasectomy

|                      | Total (n = 134) | Open (n = 50) | VATS (n = 84) | p value |
|----------------------|----------------|--------------|--------------|---------|
| Preoperative AFP (ng/ml) | 18.9 (1.1–12,000.0) | 34.9 (1.1–7330.0) | 9.9 (1.2–12,000.0) | 0.155 |
| Postoperative AFP (ng/ml) | 10.6 (0–28,200.0) | 11.8 (0–28,200.0) | 8.8 (0–18,800.0) | 0.193 |
| Local recurrence | 73 (50.3%) | 33 (66.0%) | 40 (47.6%) | 0.112 |
| Progression of local disease | 16 (11.0%) | 5 (10.0%) | 11 (13.1%) | 0.112 |
| Laterality | | | | 0.039 |
| Bilateral | 30 (22.4%) | 16 (32.0%) | 14 (16.7%) | |
| Unilateral | 104 (77.6%) | 34 (68.0%) | 70 (83.3%) | |
| Number of metastasis | 1.8 ± 1.4 | 2.2 ± 1.9 | 1.5 ± 0.9 | 0.009 |
| Size (mm) | 14.9 ± 9.4 | 16.4 ± 8.1 | 14.0 ± 10.0 | 0.143 |
| Extent of resection | | | | 0.001 |
| Wedge resection | 104 (77.6%) | 30 (60.0%) | 74 (88.1%) | |
| Segmentectomy/lobectomy | 30 (22.4%) | 20 (40.0%) | 10 (11.9%) | |
| Hospital stay (days) | 6.4 ± 4.2 | 7.9 ± 4.0 | 5.4 ± 4.1 | 0.001 |
| Complications | 6 (4.5%) | 4 (8.0%) | 2 (2.4%) | 0.195 |
| DFI from HCC (months) | 22.6 ± 17.2 | 21.8 ± 16.4 | 23.1 ± 17.7 | 0.666 |
| DFI from PM (months) | 22.3 ± 39.4 | 22.6 ± 43.7 | 22.2 ± 36.9 | 0.945 |
| Overall survival time (months) | 52.1 ± 41.0 | 56.4 ± 46.6 | 49.5 ± 37.3 | 0.377 |

VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, PM pulmonary metastasis, DFI disease-free interval

Table 3 Recurrence of metastasis from hepatocellular carcinoma after the first pulmonary metastasectomy

|                      | Total (n = 134) | Open (n = 50) | VATS (n = 84) | p value |
|----------------------|----------------|--------------|--------------|---------|
| Recurrence after metastasectomy | 113 (84.3%) | 42 (84.0%) | 71 (84.5%) | 0.936 |
| Recurred site | | | | 0.581 |
| Lung | 63 (47.0%) | 27 (54.0%) | 36 (42.9%) | |
| Liver | 26 (19.4%) | 9 (18.0%) | 17 (20.2%) | |
| Bone | 0 | 0 | 0 | |
| Brain | 2 (1.5%) | 1 (2.0%) | 1 (1.2%) | |
| Different single organ | 13 (9.7%) | 2 (4.0%) | 11 (13.1%) | |
| Multiple organs | 9 (6.7%) | 3 (6.0%) | 6 (7.1%) | |
| Pulmonary specific recurrence | 95 (70.9%) | 38 (76.0%) | 57 (67.9%) | 0.316 |
| Recurred site | | | | 0.297 |
| Ipsilateral | 43 (32.1%) | 20 (40.0%) | 23 (27.4%) | |
| Contralateral | 52 (38.8%) | 18 (36.0%) | 34 (40.5%) | |
| Treatment of recurred PM | | | | 0.533 |
| Surgery | 45 (33.6%) | 18 (36.0%) | 27 (32.1%) | |
| Chemotherapy | 27 (20.1%) | 10 (20.0%) | 17 (20.2%) | |
| Radiotherapy | 4 (3.0%) | 2 (4.0%) | 2 (2.4%) | |
| Chemoradiation | 2 (1.5%) | 2 (4.0%) | 0 | |
| Observation | 17 (12.7%) | 6 (12.0%) | 11 (13.2%) | |

VATS video-assisted thoracic surgery, PM pulmonary metastasis
Local recurrence of HCC, history of liver cirrhosis, and preoperative AFP were found to be independent prognostic factors for overall survival (Table 4). Local recurrence of HCC and TPR were independent prognostic factors for DFS after the first pulmonary metastasectomy ($p < 0.001$ and 0.005, respectively) (Table 5). For pulmonary-specific recurrence, local recurrence of HCC and preoperative AFP were independent prognostic factors ($p < 0.001$ and $p = 0.013$, respectively) (Table 6).

The patients’ characteristics after PSM are summarized in Table 7. No significant differences in baseline and PM characteristics were observed. The open group underwent more extensive surgery and stayed more days than the VATS group ($p = 0.025$ and $p = 0.017$, respectively) (Table 8). There was no significant difference in overall survival rate, DFS rate, and PDFS rate after the first pulmonary metastasectomy between the VATS and open groups ($p = 0.764$, 0.937, and 0.786, respectively) (Fig. 3).

**Discussion**

The survival rate of HCC patients has markedly improved as a result of advances in surgical techniques and perioperative management. Although the lung is the most frequent site of extrahepatic metastasis from HCC, the role of surgery for PM from HCC has not been fully clarified yet, unlike PM from colorectal cancer or osteosarcoma. There have been some reports favoring surgical resection for isolated PM from HCC, and the present study supports those results [8–10]. While median survival time and 1-year survival rate of the patients with PM treated with chemotherapy were 4.6–14 months and 20–42%, respectively [5, 8], 5-year survival rate of patients who had undergone metastasectomy was reported to be 24–41.4% [15–20].

In the present study, the 5-year DFS rate and 5-year survival rate were 20.4% and 37.3%, respectively. More long-term survivors could be found among the patients who underwent metastasectomy than among those who received chemotherapy. However, since most studies were non-randomized and included only operable and resectable lesions in the surgery group, a comparison of outcomes between metastasectomy and chemotherapy needs circumspection.

Cheng et al. reported the overall survival of patients with advanced HCC with or without sorafenib. The median overall survival period was 6.5 and 4.2 months [7]. In our study, the median overall survival period was
38.7 months (range, 4.4–172.3). There are quite a few differences between the two studies. The reason being that the previous study included patients who were not subjected to surgery.

In this series, 81 (60.4%) patients had a single PM, while only 6 (4.5%) patients had five or more PMs. This implies that patients with a less invasive disease could be selected for metastasectomy. One hundred and thirty patients with four or less PMs showed a median survival period of 40.7 months (range, 4.4–172.3) regardless of the number of PMs. To evaluate the efficacy of metastasectomy, large randomized studies are needed.

Surgical intervention for PM can provide excellent local control. Due to its low mortality and morbidity

### Table 4 Univariate and multivariate analysis for overall survival after the first pulmonary metastasectomy

| Characteristics                              | Univariate | Multivariate |
|----------------------------------------------|------------|--------------|
|                                             | p value    | HR (95% CI)  | p value |
| Age > 50 years                               | 0.375      |              |         |
| Liver cirrhosis (+)                          | 0.051      | 1.729 (1.142–2.619) | 0.010  |
| Hepatitis viral marker (+)                  | 0.457      |              |         |
| BCLC stage ≥ C                               | 0.035      |              |         |
| ECOG performance status ≥1                  | 0.089      |              |         |
| Child-Pugh score ≥ B                         | 0.025      |              |         |
| Local recurrence of HCC                     | < 0.001    | 2.495 (1.571–3.963) | < 0.001 |
| Initial AFP > 500 ng/ml                     | 0.318      |              |         |
| Preoperative AFP > 500 ng/ml                | < 0.001    | 2.632 (1.554–4.456) | < 0.001 |
| Wedge resection as metastasectomy           | 0.423      |              |         |
| Multiple PM                                 | 0.274      |              |         |
| Maximum diameter of PM > 2 cm               | 0.130      |              |         |
| Hospital days ≥ 7                           | 0.093      |              |         |
| Time-to-pulmonary recurrence period         | 0.113      |              |         |
| Open metastasectomy                         | 0.870      |              |         |

**HCC** hepatocellular carcinoma, **HR** hazard ratio, **CI** confidence interval, **AFP** alpha-fetoprotein, **BCLC** Barcelona Clinic Liver Cancer, **ECOG** Eastern Cooperative Oncology Group, **PM** pulmonary metastasis

### Table 5 Univariate and multivariate analysis for disease-free survival after the first pulmonary metastasectomy

| Characteristics                              | Univariate | Multivariate |
|----------------------------------------------|------------|--------------|
|                                             | p value    | HR (95% CI)  | p value |
| Age > 50 years                               | 0.464      |              |         |
| Liver cirrhosis (+)                          | 0.173      |              |         |
| Hepatitis viral marker (+)                  | 0.627      |              |         |
| BCLC stage ≥ C                               | 0.072      |              |         |
| ECOG performance status ≥1                  | 0.161      |              |         |
| Child-Pugh score ≥ B                         | 0.120      |              |         |
| Local recurrence of HCC                     | < 0.001    | 2.717 (1.694–4.357) | < 0.001 |
| Initial AFP > 500 ng/ml                     | 0.910      |              |         |
| Preoperative AFP > 500 ng/ml                | 0.037      |              |         |
| Wedge resection as metastasectomy           | 0.199      |              |         |
| Multiple PM                                 | 0.265      |              |         |
| Maximum diameter of PM > 2 cm               | 0.387      |              |         |
| Hospital days ≥ 7                           | 0.044      |              |         |
| Time-to-pulmonary recurrence period         | 0.068      | 1.852 (1.204–2.848) | 0.005  |
| Open metastasectomy                         | 0.943      |              |         |

**HCC** hepatocellular carcinoma, **HR** hazard ratio, **CI** confidence interval, **AFP** alpha-fetoprotein, **BCLC** Barcelona Clinic Liver Cancer, **ECOG** Eastern Cooperative Oncology Group, **PM** pulmonary metastasis
metastasectomy should be considered as a viable option to prevent pulmonary complications caused by PM. Several studies suggest that to improve long-term survival, patients with isolated PM and no other distant metastasis should be considered not only for surgical resection but also for repeated resection of PM [21–23]. In our experience, patients who underwent pulmonary metastasectomy could be discharged within approximately 7 days without operative mortality or serious complications. The second or third pulmonary metastasectomy could also be safely performed, and repeated metastasectomy could be attempted in patients with localized PM from HCC for better survival (5-year survival rate was 59.1% in repeated metastasectomy patients and 48.1% in non-surgical treatment patients, \( p = 0.002 \)).

Introduction of VATS makes metastasectomy more endurable for patients with chronic diseases such as liver cirrhosis. Less pain and shorter hospitalization can lead to earlier returns to preoperative activities or subsequent treatment [11–13, 24]. However, the inability to thoroughly palpate the lung by VATS raises concerns about incomplete metastasectomy [25, 26] which could result in significantly worse survival rates [27]. In contrast, there are reports suggesting that the outcomes of thoracosscopic surgery are not inferior to those of open thoracotomy [13, 28]. This disagreement can partly be due to the possibility that finger palpation of the lung also has limitations in terms of detecting small nodules; in addition, metastasectomy under a thoracotomy is not always complete [29]. Recently, in contrast to the inaccuracy of old-generation CT, the 1-mm-thin section 16-channel multi-detector row CT showed a high detection rate of metastatic pulmonary nodules, especially in patients with non-osteosarcoma. Therefore, it can be a possible substitute for manual palpation [14]. If diagnosis by either imaging or palpation is incomplete, VATS should be considered for metastasectomy. VATS can minimize adhesion formation and render repeated resection more amenable. Given that complete resection is most important in any situation, conversion to thoracotomy should be promptly considered if the lesions detected by CT cannot be identified or resected by VATS. In the present study, all preoperatively detected PMs were completely resected either by VATS or by open surgery. Hospitalization duration and complication rate were significantly reduced in the VATS group. However, because more segmentectomies and lobectomies were adapted in the open group, it is difficult to compare the two methods straightforwardly. To overcome the shortcomings outlined above, in the present study, the propensity score matching analysis was adapted to compare two methods, and relatively favorable results were observed. However, matched analysis needs to drop unmatched data, for which, the main drawback is the shortage of cases. For this reason, further randomized large cohort studies need to be conducted in the future.

### Table 6 Univariate and multivariate analysis for pulmonary-specific disease-free survival after the first pulmonary metastasectomy

| Characteristics                        | Univariate p value | Multivariate p value |
|----------------------------------------|---------------------|----------------------|
| Age > 50                               | 0.253               |                      |
| Liver cirrhosis (+)                    | 0.216               |                      |
| Hepatitis viral marker (+)             | 0.628               |                      |
| BCLC stage ≥ C                         | 0.023               |                      |
| ECOG performance status ≥1             | 0.020               |                      |
| Child-Pugh score ≥ B                   | 0.156               |                      |
| Local recurrence of HCC                | < 0.001             | 3.105 (1.946–4.954)  |
| Initial AFP > 500 ng/ml                | 0.955               |                      |
| Preoperative AFP > 500 ng/ml           | 0.082               | 1.978 (1.157–3.382)  |
| Wedge resection as metastasectomy      | 0.227               |                      |
| Multiple PM                            | 0.156               |                      |
| Maximum diameter of PM > 2 cm          | 0.847               |                      |
| Hospital days ≥7                       | 0.086               |                      |
| Time-to-pulmonary recurrence period    | 0.151               |                      |
| Open metastasectomy                    | 0.578               |                      |

HCC: hepatocellular carcinoma, HR: hazard ratio, CI: confidence interval, AFP: alpha-fetoprotein, BCLC: Barcelona Clinic Liver Cancer, ECOG: Eastern Cooperative Oncology Group, PM: pulmonary metastasis
In the published literature, only several studies have reported risk factors related to long-term survival. Complete resection is the most significant predictor of better survival [18–20, 27]. Worse survival can be expected for patients with the factors causing a rise in the possibility of incomplete resection including multiple lesions [16, 30] and the factors predicting aggressive disease, such as short disease-free interval [18–20, 27, 30–33], multiple PMs, and higher serum AFP levels [19, 20]. It was suggested that the size of nodules had an inverse correlation with survival in PM from cancer other than HCC [22]. In the present study, local recurrence or progression of HCC, history of liver cirrhosis, and preoperative AFP were found to be independent prognostic factors for overall survival after the first pulmonary metastasectomy. Local recurrence or progression of HCC and preoperative AFP were also found to be independent prognostic factors for pulmonary-specific recurrence. Therefore, our results suggest that if there is a local recurrence or progression of HCC or if the levels of AFP before surgery are high, decisions on surgical treatments should be made with caution. The impact of all these proposed factors needs to be verified in future large-scale studies.

**Conclusion**

When metastasis confined to the lung with the HCC under control or controllable, metastasectomy can be

---

| Table 7 Baseline characteristics of open and VATS group after propensity score matching |
|----------------------------------|-----------------|-----------------|-----------------|-----------------|
| Age (years)                      | 54.0 ± 11.1     | 54.8 ± 9.3      | 53.2 ± 12.7     | 0.606           |
| Sex (male)                       | 51 (87.9%)      | 26 (89.7%)      | 25 (86.2%)      | 0.687           |
| BCLC stage                       | 0               | 0               | 0               | 0.284           |
| A                                | 13 (22.4%)      | 9 (31.0%)       | 4 (13.8%)       |                 |
| B                                | 21 (36.2%)      | 9 (31.0%)       | 12 (41.4%)      |                 |
| C                                | 24 (41.4%)      | 11 (38.0%)      | 13 (44.8%)      |                 |
| D                                | 0               | 0               | 0               |                 |
| ECOG performance status          | 0.339           |                 |                 |                 |
| 0                                | 49 (84.5%)      | 24 (82.8%)      | 25 (86.2%)      |                 |
| 1                                | 7 (12.1%)       | 3 (10.3%)       | 4 (13.8%)       |                 |
| 2                                | 2 (3.4%)        | 2 (6.9%)        | 0               |                 |
| 3                                | 0               | 0               | 0               |                 |
| 4                                | 0               | 0               | 0               |                 |
| Etiology                         | 0.362           |                 |                 |                 |
| HBV                              | 46 (79.3%)      | 24 (82.8%)      | 22 (75.9%)      |                 |
| HCV                              | 1 (1.7%)        | 0               | 1 (3.4%)        |                 |
| Alcohol                          | 2 (3.4%)        | 0               | 2 (6.9%)        |                 |
| Unknown                          | 9 (15.5%)       | 5 (17.2%)       | 4 (13.8%)       |                 |
| Child-Pugh classification        | 0.706           |                 |                 |                 |
| A                                | 50 (86.2%)      | 24 (82.8%)      | 26 (89.7%)      |                 |
| B                                | 8 (13.8%)       | 5 (17.2%)       | 3 (10.3%)       |                 |
| C                                | 0               | 0               | 0               |                 |
| Liver cirrhosis                  | 0.401           |                 |                 |                 |
| 19 (32.8%)                       | 11 (37.9%)      | 8 (27.6%)       |                 |
| Treatment of HCC                 | 0.730           |                 |                 |                 |
| Surgery                          | 48 (82.8%)      | 23 (89.3%)      | 25 (86.2%)      |                 |
| TACE                             | 10 (17.2%)      | 6 (20.7%)       | 4 (13.8%)       |                 |
| RFA                              | 0               | 0               | 0               |                 |

VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HBV hepatitis B virus, HCV hepatitis C virus, BCLC Barcelona Clinic Liver Cancer, PSM propensity score matching, ECOG Eastern Cooperative Oncology Group, TACE transarterial chemoembolization, RFA radiofrequency ablation.
positively considered for patients with sufficient pulmonary reserve and in a good general condition. Local recurrence or progression of HCC, history of liver cirrhosis, and preoperative AFP were found to be independent prognostic factors. If there is a local recurrence or progression of HCC or if the level of AFP before metastasectomy is high, decisions on surgical treatment should be made with caution.

According to the results of the propensity score matching analysis, VATS metastasectomy provided outcomes comparable to those afforded by open metastasectomy. The most important prerequisite for pulmonary metastasectomy is complete resection.

**Table 8** Surgical characteristics of open and VATS group after propensity score matching

|                          | Total (n = 58) | Open (n = 29) | VATS (n = 29) | p value |
|--------------------------|---------------|--------------|--------------|---------|
| Preoperative AFP (ng/ml) | 6.9 (0.6–12,000.0) | 11.6 (1.1–6610.0) | 4.7 (0.6–12,000.0) | 0.981   |
| Local recurrence         | 36 (62.1%)    | 17 (58.6%)   | 19 (65.5%)   | 0.373   |
| Progression of local disease | 5 (8.6%) | 4 (13.8%) | 1 (3.4%) | 0.570   |
| Laterality               |               |              |              |         |
| Unilateral               | 40 (69.0%)    | 19 (65.5%)   | 21 (72.4%)   |         |
| Bilateral                | 18 (31.0%)    | 10 (34.5%)   | 8 (27.6%)    |         |
| Number of metastasis     | 1.9 ± 1.4     | 2.1 ± 1.6    | 1.8 ± 1.3    | 0.414   |
| Size (mm)                | 15.8 ± 8.8    | 16.9 ± 9.3   | 14.7 ± 8.2   | 0.343   |
| Extent of resection      |               |              |              |         |
| Wedge resection          | 46 (79.3%)    | 19 (65.5%)   | 27 (93.1%)   | 0.025   |
| Segmentectomy/lobectomy  | 12 (20.7%)    | 10 (34.5%)   | 2 (6.9%)     |         |
| Hospital stay (days)     | 6.2 ± 3.7     | 7.4 ± 3.0    | 5.1 ± 3.9    | 0.017   |
| Complications            | 1 (1.7%)      | 1 (3.4%)     | 0            | 0.313   |
| DFI from HCC (months)    | 24.0 ± 19.0   | 21.5 ± 16.0  | 26.5 ± 21.5  | 0.312   |
| DFI from PM (months)     | 16.4 ± 28.0   | 14.9 ± 26.2  | 17.9 ± 30.1  | 0.683   |
| Recurrence after metastasectomy | 51 (87.9%) | 27 (93.1%) | 24 (82.8%) | 0.227   |
| Recurrence including PM  | 40 (69.0%)    | 23 (79.3%)   | 17 (58.6%)   | 0.089   |
| Overall survival time (months) | 49.2 ± 37.4 | 52.5 ± 38.1 | 46.0 ± 37.0 | 0.513   |

VATS video-assisted thoracic surgery, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, PM pulmonary metastasis, DFI disease-free interval

Fig. 3 Survival rate after the first pulmonary metastasectomy in matched group; overall survival rate (a), disease-free survival rate (b), pulmonary specific disease-free survival rate (c).
Abbreviations

HCC: Hepatocellular carcinoma; PM: Pulmonary metastasis; SHARP: Sorafenib HCC Assessment Randomized Protocol; HR: Hazard ratio; VATS: Video-assisted thoracic surgery; CT: Computed tomography; TPR: Time-to-pulmonary recurrence; DFS: Disease-free survival; PDFS: Pulmonary DFS after metastasectomy; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer; PSM: Propensity score matching; ECOG: Eastern Cooperative Oncology Group

Acknowledgements

Not applicable

Authors’ contributions

Conception and design: HR Kim. Provision of study materials or patients: GD Lee, SH Choi, Y-H Kim, DK Kim, S-I Park, HR Kim. Collection and analysis of data: HP Lee, JK Yun, HS Jung, DH Moon, HR Kim. Manuscript writing: HP Lee, HR Kim. Final approval of manuscript: All authors.

Funding

No financial or material support was obtained for this study.

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

This study was approved by the Asan Medical Center Ethics Committee/Institutional Review Board (2019-1166).

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Author details

1. Department of Thoracic & Cardiovascular Surgery, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Republic of Korea.
2. Department of Thoracic & Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
3. Department of Thoracic and Cardiovascular Surgery, CHA Bundang Medical Center, CHA University, Seoul, Republic of Korea.
4. Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.

Received: 3 September 2020 Accepted: 19 January 2021

Published online: 30 January 2021

References

1. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS, et al. for the Organizing Committee of Japan-Korea Liver Symposium (JKLS). Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology. 2008;75(Suppl 1):1–3.
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.
3. Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Clinical features of hepatocellular carcinoma with extraprotected metastases. J Gastroenterol Hepatol. 2005;20(11):1781–7.
4. Okusaka T, Okuda S, Ishi H, Nose H, Nagahama H, Nakasuka H, et al. Prognosis of hepatocellular carcinoma patients with extraprotected metastases. Hepatogastroenterology. 1997;44(139):251–7.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
6. Cheng AL, Guan Z, Chen Z, Tao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the Phase III sorafenib Asia-Pacific Trial. Eur J Cancer. 2012;48(10):1452–65.
7. Lam CM, Lo CM, Yuen WK, Liu CL, Fan ST. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. Br J Surg. 1998;85(9):1198–200.
8. Tomimaru Y, Saiuki Y, Yamada T, Eguchi H, Takami K, Ohgishii H, et al. The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg. 2006;192(1):46–51.
9. Kwon JB, Park K, Kim YD, Seo JH, Moon SW, Cho DG, et al. Clinical outcome after pulmonary metastasectomy from primary hepatocellular carcinoma: analysis of prognostic factors. World J Gastroenterol. 2008;14(37):5717–22.
10. Mutsaerts ET, Zoetmulder FA, Meijer S, Baas P, Hart AA, Rutgers EJ. Outcome of thoracoscopical pulmonary metastasectomy evaluated by confirmatory thoracotomy. Ann Thorac Surg. 2001;72(2):230–2.
11. Lin JC, Wiechmann RJ, Sower MF, Haakelegg SR, Ferson PF, Naunheim KS, et al. Diagnostic and therapeutical video-assisted thoracic surgery resection of pulmonary metastases. Surgery. 1999;126(4):636–41 discussion 641.
12. Nakajima J, Takamoto S, Tanaka M, Takeuchi E, Murakawa T, Fukumi T. Thoracoscopic surgery and conventional open thoracotomy in metastatic lung cancer. Surg Endosc. 2001;15(8):849–53.
13. Kang MC, Kang CH, Lee HJ, Goo JM, Kim YT, Kim JH. Accuracy of 16-channel multi-detector row chest computed tomography with thin sections in the detection of metastatic pulmonary nodules. Eur J Cardio Thorac Surg. 2008;33(3):473–9.
14. Koido N, Kondo H, Suzuki K, Asamura H, Shimada K, Tsuchiya R. Surgical treatment of pulmonary metastasis from hepatocellular carcinoma. Hepatogastroenterology. 2007;54(73):152–6.
15. Kawamura M, Nakajima J, Matsuuga H, Horio H, Miyoshi S, Nakagawa K, et al. Metastatic lung tumor study group of Japan. Surgical outcomes for pulmonary metastases from hepatocellular carcinoma. Eur J Cardio Thorac Surg. 2008;34(1):196–9.
16. Nakajima J, Tanaka M, Matsusato J, Takeuchi E, Fukami T, Takamoto S, Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma. World J Surg. 2005;29(6):715–8.
17. Kitano K, Murayama T, Sakamoto M, Nagayama K, Ueno K, Murakawa T, et al. Outcome and survival analysis of pulmonary metastasectomy for hepatocellular carcinoma. Eur J Cardio Thorac Surg. 2012;41(2):376–82.
18. Ohba T, Yano T, Yoshida T, Kawanishi D, Tsukamoto S, Shoji F, et al. Results of a surgical resection of pulmonary metastasis from hepatocellular carcinoma: prognostic impact of the preoperative serum alpha-fetoprotein level. Surg Today. 2012;42(6):526–31.
19. Takahashi Y, Ikeda N, Nakajima J, Sawabata N, Chida M, Horio H, et al. Prognostic analysis of surgical resection for pulmonary metastasis from hepatocellular carcinoma. World J Surg. 2016;40(9):2178–85.
20. Welter S, Jacobs J, Krake B, Krebs S, Stamatis G. Long-term survival after repeated resection of pulmonary metastases from colorectal cancer. Ann Thorac Surg. 2007;84(1):203–10.
21. Porzelt AJ, Luterain A, Weyland B, Humblet Y, Noihoime P, Groupe d’Oncologie Thoracique Des Cliniques Saint-Luc. Prognostic factors for long-term survival in patients with thoracic metastatic disease: a 10-year experience. Eur J Cardio Thorac Surg. 2007;31(2):173–80.
22. Pfannschmidt J, Klocke J, Muley T, Hoffmann H, Diemennan H. Pulmonary resection for metastatic osteosarcoma: a retrospective analysis of 21 patients. Thorac Cardiovasc Surg. 2006;54(2):120–3.
23. Petersen RP, Pham D, Burtle WD, Hanish S, Toloza EM, Harpole DH, et al. Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. Ann Thorac Surg. 2007;83(4):1245–9 discussion 1250.
24. McCormack PM, Bains MS, Begg CB, Metaxas RJ, Panicek DM, et al. Role of video-assisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg. 1996;62(1):213–6 discussion 216.
25. Margaritora S, Porzella V, D’Andrilli A, Cesario A, Galetta D, Macis G, et al. Pulmonary metastases: can accurate radiological evaluation avoid thoracotomic approach? Eur J Cardio Thorac Surg. 2002;21(6):1111–4.
26. Pastinonio U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5260 cases. J Thorac Cardiovasc Surg. 1997;113(3):37–49.
27. Mutsaerts ET, Zoetmulder FA, Meijer S, Baas P, Hart AA, Rutgers EJ. Long term survival of thoracoscopic metastasectomy vs metastasectomy by thoracotomy in patients with a solitary pulmonary lesion. Eur J Surg Oncol. 2002;28(8):864–8.
29. Nakajima J, Murakawa T, Fukami T, Sano A, Sugiura M, Takamoto S. Is finger palpation at operation indispensable for pulmonary metastasectomy in colorectal cancer? Ann Thorac Surg. 2007;84(5):1680–4.
30. Nakagawa T, Kameyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg. 2006;131(6):1248–54.
31. Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM, et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol. 2007;14(2):992–7.
32. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89(3):500–7.
33. Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology. 1996;111(3):720–6.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.